Literature DB >> 8078069

Lambda cI repressor mutants altered in transcriptional activation.

P Kolkhof1, B Müller-Hill.   

Abstract

We analysed the in vivo functions of three lambda cI repressor mutants which are phenotypically defective in positive control (pc). For this purpose, we constructed a lambda cI repressor expression system which allows controlled expression of various amounts of lambda cI repressor or its mutants. A five-fold activation of the PRM promoter by wild-type lambda cI repressor is measured in this in vivo system. Two of the pc mutants (pc 1: G43-R and pc 3: E34-K) repress the PRM promoter over a wide range of intracellular concentrations, the lowest being almost identical to the concentration of wild-type lambda cI repressor at which it activates the transcription of its own gene. Only the third pc mutant (pc 2: D38-N) behaves in a manner that would be expected of a true pc mutant, which is unaffected in its DNA binding activity but has lost its activation function. We studied the DNA binding properties of cI repressor and its three pc mutants with a variety of operator constructs in vivo and found that the four repressor proteins differed significantly with respect to their affinities for all operators tested. We also probed the necessity of an acidic residue at position 38 of cI repressor for activation and found that the substitution of aspartic acid 38 by tyrosine does not reduce activation of PRM. Furthermore a substitution with phenylalanine improves the activator function of cI repressor. Our results suggest that amino acid replacements at position 34 or 43 of lambda cI repressor predominantly affect the binding properties of the repressor while some hydrophobic amino acid residues at position 38 are at least as functional in activation as the acidic wild-type amino acid residue.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8078069     DOI: 10.1006/jmbi.1994.1554

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  8 in total

1.  Changing the mechanism of transcriptional activation by phage lambda repressor.

Authors:  M Li; W R McClure; M M Susskind
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

Review 2.  Aspects of protein-DNA interactions: a review of quantitative thermodynamic theory for modelling synthetic circuits utilising LacI and CI repressors, IPTG and the reporter gene lacZ.

Authors:  Peter D Munro; Gary K Ackers; Keith E Shearwin
Journal:  Biophys Rev       Date:  2016-11-07

3.  Further genetic analysis of the activation function of the TyrR regulatory protein of Escherichia coli.

Authors:  J Yang; H Camakaris; A J Pittard
Journal:  J Bacteriol       Date:  1996-02       Impact factor: 3.490

4.  DNA footprinting and biophysical characterization of the controller protein C.AhdI suggests the basis of a genetic switch.

Authors:  S D Streeter; I Papapanagiotou; J E McGeehan; G G Kneale
Journal:  Nucleic Acids Res       Date:  2004-12-08       Impact factor: 16.971

5.  Engineering orthogonal dual transcription factors for multi-input synthetic promoters.

Authors:  Andreas K Brödel; Alfonso Jaramillo; Mark Isalan
Journal:  Nat Commun       Date:  2016-12-16       Impact factor: 14.919

6.  Regulatory circuit based on autogenous activation-repression: roles of C-boxes and spacer sequences in control of the PvuII restriction-modification system.

Authors:  Iwona Mruk; Preeti Rajesh; Robert M Blumenthal
Journal:  Nucleic Acids Res       Date:  2007-10-11       Impact factor: 16.971

7.  Real-time kinetics of restriction-modification gene expression after entry into a new host cell.

Authors:  Iwona Mruk; Robert M Blumenthal
Journal:  Nucleic Acids Res       Date:  2008-03-11       Impact factor: 16.971

8.  Natural C-independent expression of restriction endonuclease in a C protein-associated restriction-modification system.

Authors:  Monika Rezulak; Izabela Borsuk; Iwona Mruk
Journal:  Nucleic Acids Res       Date:  2015-12-09       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.